Amphastar Pharmaceuticals AMPH Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Amphastar Pharmaceuticals (AMPH) reported accounts payable and other current liabilities (note 11) of $152.69M in Q1 2026.
- How has Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
- Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11) decreased by 13.2% year-over-year, from $175.94M to $152.69M.
- What is the long-term trend for Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 9.2% compound annual growth rate (CAGR), from $95.5M to $148.35M.